HK1213815A1 - 合成種 抑制劑的方法 - Google Patents

合成種 抑制劑的方法

Info

Publication number
HK1213815A1
HK1213815A1 HK16101930.3A HK16101930A HK1213815A1 HK 1213815 A1 HK1213815 A1 HK 1213815A1 HK 16101930 A HK16101930 A HK 16101930A HK 1213815 A1 HK1213815 A1 HK 1213815A1
Authority
HK
Hong Kong
Prior art keywords
cetp
synthesizing
inhibitor
cetp inhibitor
inhibitor cetp
Prior art date
Application number
HK16101930.3A
Other languages
English (en)
Inventor
Aaron S Cote
Ross A Miller
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of HK1213815A1 publication Critical patent/HK1213815A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16101930.3A 2005-07-01 2016-02-22 合成種 抑制劑的方法 HK1213815A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69623305P 2005-07-01 2005-07-01

Publications (1)

Publication Number Publication Date
HK1213815A1 true HK1213815A1 (zh) 2016-07-15

Family

ID=37604801

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101930.3A HK1213815A1 (zh) 2005-07-01 2016-02-22 合成種 抑制劑的方法

Country Status (8)

Country Link
US (1) US7863307B2 (zh)
EP (2) EP1901741B1 (zh)
JP (2) JP5112307B2 (zh)
CN (2) CN101212966B (zh)
AU (1) AU2006265975B2 (zh)
CA (1) CA2612142A1 (zh)
HK (1) HK1213815A1 (zh)
WO (1) WO2007005572A1 (zh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863307B2 (en) * 2005-07-01 2011-01-04 Merck Sharp & Dohme Process for synthesizing a CETP inhibitor
EP1965764B1 (en) 2005-12-05 2011-07-13 Merck Sharp & Dohme Corp. Self-emulsifying formulations of cetp inhibitors
JP5229567B2 (ja) * 2005-12-30 2013-07-03 メルク・シャープ・アンド・ドーム・コーポレーション Ｃｅｔｐ阻害剤
CN103735515A (zh) * 2006-02-09 2014-04-23 默沙东公司 Cetp抑制剂的聚合物制剂
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2136637B1 (en) 2007-03-16 2015-11-11 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
EP2245022A4 (en) 2008-02-25 2012-02-22 Panmira Pharmaceuticals Llc ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN103816158A (zh) 2008-08-15 2014-05-28 勃林格殷格翰国际有限公司 用于治疗fab-相关疾病的嘌呤衍生物
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
NZ592924A (en) 2008-12-23 2014-05-30 Boehringer Ingelheim Int Salt forms of a xanthine derivative
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
WO2010092163A2 (en) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Antidiabetic medications
EP2470189A4 (en) * 2009-08-27 2013-01-23 Merck Sharp & Dohme METHODS FOR PREPARING HEPATITIS C VIRUS PROTEASE INHIBITORS
KR101763659B1 (ko) 2009-10-02 2017-08-01 베링거 인겔하임 인터내셔날 게엠베하 Ｂｉ―1356 및 메트포르민을 포함하는 약제학적 조성물
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US10501817B2 (en) 2010-03-16 2019-12-10 Imperial Sugar Company Process for the manufacture of co-crystallized sucrose natural sweeteners and the products thereof
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
KR101819609B1 (ko) 2010-05-05 2018-01-17 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
EP2397473A1 (en) 2010-06-14 2011-12-21 LEK Pharmaceuticals d.d. A stable highly crystalline anacetrapib
KR102018038B1 (ko) 2010-06-24 2019-09-05 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2468736A1 (en) * 2010-12-23 2012-06-27 LEK Pharmaceuticals d.d. Synthesis of intermediates for preparing anacetrapib and derivates thereof
EP2468735A1 (en) 2010-12-23 2012-06-27 LEK Pharmaceuticals d.d. Synthesis of intermediates for preparing anacetrapib and derivates thereof
HUE043540T2 (hu) 2011-07-15 2019-08-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
WO2013066768A1 (en) * 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Process for a cetp inhibitor
WO2013064188A1 (en) 2011-11-03 2013-05-10 Lek Pharmaceuticals D.D. A stable highly crystalline anacetrapib
CN102516237B (zh) * 2011-12-05 2014-02-26 成都苑东药业有限公司 一种恶唑烷酮类化合物
WO2013091696A1 (en) 2011-12-21 2013-06-27 Lek Pharmaceuticals D.D. Synthesis of intermediates for preparing anacetrapib and derivatives thereof
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
CN102603499A (zh) * 2012-03-01 2012-07-25 南京药石药物研发有限公司 1-溴-4-氟-5-异丙基-2-甲氧基苯的合成方法
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013174768A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
WO2014012428A1 (zh) * 2012-07-19 2014-01-23 上海恒瑞医药有限公司 噁唑烷酮类衍生物、其制备方法及其在医药上的应用
WO2014111953A1 (en) * 2013-01-17 2014-07-24 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of anacetrapib and intermediates thereof
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
CN103113193A (zh) * 2013-03-05 2013-05-22 华东师范大学 一种2-氯-5-三氟甲基苄醇的合成方法
BR112015020209A2 (pt) 2013-03-15 2017-07-18 Boehringer Ingelheim Int uso de linagliptina em terapia antidiabética de proteção cardíaca e renal
CN103265413A (zh) * 2013-05-15 2013-08-28 华东师范大学 一种4’-氟-2’-甲氧基-5’-异丙基-4-三氟甲基-1,1’-联苯-2-甲醇的合成方法
CN104955816B (zh) * 2014-01-14 2016-08-31 杭州普晒医药科技有限公司 一种安塞曲匹的晶型及其制备方法、其药物组合物和用途
CN104557758A (zh) * 2014-05-04 2015-04-29 广东东阳光药业有限公司 一种cetp抑制剂的非晶型
RU2703192C2 (ru) 2014-07-30 2019-10-15 Ф. Хоффманн-Ля Рош Аг Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами
WO2016067194A1 (en) * 2014-10-27 2016-05-06 Sun Pharmaceutical Industries Limited Process for the preparation of anacetrapib and an intermediate thereof
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN106749075A (zh) * 2016-11-24 2017-05-31 山东新华制药股份有限公司 阿那曲波的恶唑烷酮中间体的晶型及其制备方法
WO2020016230A1 (en) 2018-07-17 2020-01-23 Boehringer Ingelheim International Gmbh Cardio- and renosafe antidiabetic therapy
AU2019304485B2 (en) 2018-07-17 2024-10-31 Boehringer Ingelheim International Gmbh Cardiosafe antidiabetic therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
HN2005000340A (es) * 2004-07-02 2009-11-06 Merck Sharp & Dohme Inhibidores de cetp
US7863307B2 (en) * 2005-07-01 2011-01-04 Merck Sharp & Dohme Process for synthesizing a CETP inhibitor

Also Published As

Publication number Publication date
AU2006265975B2 (en) 2011-12-15
EP1901741A1 (en) 2008-03-26
WO2007005572A1 (en) 2007-01-11
EP1901741A4 (en) 2010-08-04
CN102757397A (zh) 2012-10-31
EP2985022B1 (en) 2018-09-12
CN101212966A (zh) 2008-07-02
JP2009500341A (ja) 2009-01-08
JP5112307B2 (ja) 2013-01-09
US7863307B2 (en) 2011-01-04
CN101212966B (zh) 2012-03-14
AU2006265975A1 (en) 2007-01-11
EP2985022A1 (en) 2016-02-17
US20100041724A1 (en) 2010-02-18
CA2612142A1 (en) 2007-01-11
JP2013014594A (ja) 2013-01-24
EP1901741B1 (en) 2015-09-16

Similar Documents

Publication Publication Date Title
HK1213815A1 (zh) 合成種 抑制劑的方法
IL194508A0 (en) Process for synthesizing organoelemental compounds
AP2009004746A0 (en) Process for prepaiIrng diaminophenothiazinium compounds
EP1971595A4 (en) CETP INHIBITORS
EP1973889A4 (en) CETP INHIBITORS
SG132583A1 (en) Strip process for superalloys
ZA200705157B (en) Process for making a germanium-zeolite
ZA200705155B (en) Process for making a germanium-zeolite
ZA200608083B (en) Process for preparing 5-methyl-2-furfural
PT1969183E (pt) Processo para a produção de papel
PL1767528T3 (pl) Sposób wytwarzania związku 5-hydroksy-4-tiometylopirazolowego
TWI372145B (en) Process for preparing alkylanilides
EP1944376A4 (en) PROCESS FOR PRODUCING AN AMIDE COMPOUND
IL178415A0 (en) A process for synthesizing baccatin iii compounds
IL187004A0 (en) Process for preparing renin inhibitors
EP2010183A4 (en) PROCESS FOR SYNTHESIS OF 7-ALKINYL-4-AMINOCHINAZOLINES AND A RELATED INTERMEDIATE COMPOUND
GB0614245D0 (en) Synthesis process
EP1951053A4 (en) CETP INHIBITORS
GB0500604D0 (en) Novel process
PT1882062E (pt) Processo para a produção de papel
PL3284458T3 (pl) Sposób wytwarzania pastylek do ssania zawierających NLPZ
GB0519758D0 (en) Novel process
HK1120784A1 (en) A process for preparing beta-ketoester compounds
GB0526474D0 (en) Novel process
IL189574A0 (en) Process for preparing 1-substituted-5-acylimidazole compounds